Treatments for fibrous blood clots caused by mRNA injections

From this lengthy article by the Epoch Times article here:

Why Strange Clots Form After mRNA Jabs, Treatments to Consider (theepochtimes.com)

https://www.theepochtimes.com/health/why-strange-clots-form-after-mrna-jabs-treatments-to-consider_4914851.html

There is this:

“Treatment Strategies for Vaccine-Induced Unusual Clots

It has been reported that “suitable and closely monitored ‘triple’ anticoagulant therapy leads to the removal of the microclots.” “Triple” anticoagulant therapy normally includes an oral anticoagulant plus two drugs designed to decrease platelet activation.

Anticoagulants are one of two (along with antiplatelet) classes of antithrombotic drugs, also called blood thinning drugs or blood thinners. Anticoagulants act on the clotting cascade and keep it from completion.

However, a UK-wide trial found that a drug used to reduce the risk of blood clots does not help patients recovering from moderate or severe COVID-19.

Because of the difference in the components of vaccine-induced clots versus normal blood clots, blood-thinning drugs may not work in vaccinated people.

If the spike-formed amyloid substances are the main component of the fibrous clots, in addition to an autophagy-boosting strategy to remove as much as possible of the spike protein, an exploration of the potential therapies or compounds with anti-amyloid effects may be considered to help reduce abnormal blood clots after vaccination.

1. Targeted Therapies

Insights could be gained from the treatment of amyloidosis, including the use of monoclonal antibodies.

A monoclonal antibody is a type of targeted therapy. It recognizes and attaches to a specific protein. A monoclonal antibody could be designed to target the amyloid directly.

2. Nutraceuticals Effective in Reducing Amyloid

Amyloid is a type of misfolded protein, and it is this misfolding that shapes lengthy fibers. If we can correct the protein misfolding process, that could inhibit the development of long fibers.

Natural compounds may emerge as promising, new therapeutic approaches to intervening in protein-misfolding processes.

The polyphenol epi-gallocatechine-3-gallate (EGCG), the primary polyphenol in tea, binds directly to many proteins involved in protein misfolding diseases and inhibits the process of forming fibrils.

EGCG promotes the formation of stable, spherical aggregates, which are not toxic to living cells.

Derivatives of orcein, a phenoxazine dye that can be isolated from the lichen Roccella tinctoria, form a second promising class of natural compounds. They accelerate the fibril formation of the Alzheimer’s disease-related amyloid-beta peptide.

The following compounds reduce amyloid-related burdens in animal models. They may help reduce COVID vaccine-caused formation of amyloid-like fibrous clots.

Curcumin reduced amyloid levels in the brains of mice with Alzheimer’s disease. Ferulic acid, myricetin, nordihydroguaiaretic acid, and resveratrol have had similar effects in animal models.

Please speak with your physician before exploring the potential benefits of any of the above-mentioned potential therapies.

3. Meditation May Reduce Amyloid

A study published in Translational Psychiatry in 2016 followed 64 healthy women, half of whom were given a vacation, while the other half meditated.

After one week, researchers found that the meditators had significantly lower serum levels of Aβ40 (a 40-amino-acid proteolytic product from the amyloid precursor protein), which implies the potential effects of meditation in reducing amyloid-like substances.”